1. Academic Validation
  2. Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4

Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4

  • Blood Cancer J. 2019 Feb 11;9(2):19. doi: 10.1038/s41408-019-0173-0.
Yuan Xiao Zhu 1 Chang-Xin Shi 1 Laura A Bruins 1 Xuewei Wang 2 Daniel L Riggs 1 Brooke Porter 1 Jonathan M Ahmann 1 Cecilia Bonolo de Campos 1 Esteban Braggio 1 P Leif Bergsagel 1 A Keith Stewart 3 4
Affiliations

Affiliations

  • 1 Division of Hematology, Mayo Clinic, Scottsdale, AZ, USA.
  • 2 Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
  • 3 Division of Hematology, Mayo Clinic, Scottsdale, AZ, USA. stewart.keith@mayo.edu.
  • 4 Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA. stewart.keith@mayo.edu.
Abstract

To understand immunomodulatory drug (IMiD) resistance in multiple myeloma (MM), we created isogenic human multiple myeloma cell lines (HMCLs) sensitive and resistant to lenalidomide, respectively. Four HMCLs were demonstrated to be resistant to all IMiDs including lenalidomide, pomalidomide, and CC-220, but not to Bortezomib. In three HMLCs (MM.1.SLenRes, KMS11LenRes and OPM2LenRes), CRBN abnormalities were found, including chromosomal deletion, point mutation, and low CRBN expression. The remaining HMCL, XG1LenRes, showed no changes in CRBN but exhibited CD147 upregulation and impaired IRF4 downregulation after lenalidomide treatment. Depletion of CD147 in XG1LenRes and three additional HMCLs had no significant impact on MM viability and lenalidomide response. Further analysis of XG1LenRes demonstrated increased IL6 expression and constitutive STAT3 activation. Inhibition of STAT3 with a selective compound (PB-1-102) re-sensitized XG1LenRes to lenalidomide. Since XG1LenRes harbors a truncated IRF4 that is not downregulated by lenalidomide, we targeted IRF4/MYC axis with a selective inhibitor of the bromodomain of CBP/EP300 (SGC-CBP30), which restored lenalidomide response in XG1LenRes. This strategy also appeared to be more broadly applicable as SGC-CBP30 could re-sensitize two resistant HMCLs with low but detectable CRBN expression to lenalidomide, suggesting that targeting CBP/E300 is a promising approach to restore IMiD sensitivity in MM with detectable CRBN expression.

Figures
Products